NeoImmuneTech Balance Sheet Health
Financial Health criteria checks 6/6
NeoImmuneTech has a total shareholder equity of ₩66.6B and total debt of ₩0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₩80.6B and ₩13.9B respectively.
Key information
0%
Debt to equity ratio
₩0
Debt
Interest coverage ratio | n/a |
Cash | ₩60.38b |
Equity | ₩66.63b |
Total liabilities | ₩13.94b |
Total assets | ₩80.57b |
Financial Position Analysis
Short Term Liabilities: A950220's short term assets (₩65.1B) exceed its short term liabilities (₩11.5B).
Long Term Liabilities: A950220's short term assets (₩65.1B) exceed its long term liabilities (₩2.4B).
Debt to Equity History and Analysis
Debt Level: A950220 is debt free.
Reducing Debt: A950220 has no debt compared to 5 years ago when its debt to equity ratio was 1%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A950220 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A950220 has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 24.1% each year.